EDITORIAL COMMENT

Multiparametric MRI (mpMRI) is increasingly used as part of the diagnostic evaluation for prostate cancer (PCa). While mpMRI with targeted biopsy appears to increase the detection of clinically-significant cancer and reduce overdiagnosis of low-risk cancer, 1 Ahmed HU El-Shater Bosaily A Brown LC et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer(PROMIS): a paired validating confirmatory study. Lancet. 2017; 389: 815-822https://doi.org/10.1016/S0140-6736(16)32401-1 Abstract Full Text Full Text PDF PubMed Scopus (1579) Google Scholar a substantial proportion of Grade Group ≥2 (GG ≥2) lesions are not visible on mpMRI. 2 Salami SS Kaplan JB Nallandhighal S et al. Biologic significance of magnetic resonance imaging invisibility in localized prostate cancer. JCO Precis Oncol. 2019; : 1-12https://doi.org/10.1200/po.19.00054 Crossref Google Scholar ,3 Johnson DC Raman SS Mirak SA et al. Detection of individual prostate cancer foci via multiparametric magnetic resonance maging. Eur Urol. 2019; 75: 712-720https://doi.org/10.1016/j.eururo.2018.11.031 Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar The clinical significance of mpMRI-invisible lesions remains unclear, and limited data exist describing the course of mpMRI-negative PCa.